Clinical trial · Interventional
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin's Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bleomycin | Drug | Bleomycin | ALIAS |
| Dacarbazine | Drug | Dacarbazine | ALIAS |
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Rituximab | Biological | Rituximab | ALIAS |
| Vinblastine | Drug | Vinblastine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- R-ABVD
- description
- ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m\^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m\^2 Cycles 2, 4, and 6 Day 1.
- interventionNames
- Drug: Bleomycin
- Biological: Rituximab
- Drug: Dacarbazine
- Drug: Doxorubicin
- Drug: Vinblastine
Primary outcomes (2)
- measure
- Effect of Rituximab on EBV(+) Tumors
- timeFrame
- Up to 56 months
- description
- Number of relapses among participants who had tumors positive for Epstein-Barr virus (EBV).
- measure
- Relationship Between Marker Detection and Clinical Outcome
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed classical Hodgkin's lymphoma * No lymphocyte-predominant histology * Stage II, III, or IV disease * Newly diagnosed disease PATIENT CHARACTERISTICS: * Performance status 0-2 * Creatinine \< 2.0 mg/dL * Bilirubin \< 5 mg/dL * Not pregnant or nursing * No HIV positivity * Hepatitis B surface antigen negative * No active concurrent malignancy except for superficial nonmelanoma skin cancer or cervical carcinoma in situ PRIOR CONCURRENT THERAPY: * No prior chemotherapy or radiotherapy for Hodgkin's lymphoma * Steroids allowed if medically required before chemotherapy initiation
References
Publications (1)
- BACKGROUNDKasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 3;119(18):4129-32. doi: 10.1182/blood-2012-01-402792. Epub 2012 Feb 16. PMID 22343727